XML 51 R31.htm IDEA: XBRL DOCUMENT v3.23.3
COMMITMENTS AND CONTINGENCIES (Details)
 12 Months Ended
Dec. 31, 2022
USD ($)
D
item
$ / shares
shares
Sep. 30, 2023
$ / shares
shares
Dec. 31, 2021
$ / shares
shares
COMMITMENTS AND CONTINGENCIES      
Common stock, par value (in dollars per share) | $ / shares $ 0.0001 $ 0.0001 $ 0.0001
Preferred Stock, Shares Authorized | shares   10,000,000  
Preferred stock, par value (in dollars per share) | $ / shares   $ 0.0001  
MedTech Acquisition Corp      
COMMITMENTS AND CONTINGENCIES      
Maximum number of demands for registration of securities | item 3    
Legal fees $ 508,525    
Investment advisory fees 400,000    
Legal fees upon merger 479,262    
Business combination related costs $ 40,000,000    
Number of trading | D 30    
Period of stockholder approval after delivering business combination 25 days    
Preferred Stock, Shares Authorized | shares 1,000,000   1,000,000
Preferred stock, par value (in dollars per share) | $ / shares $ 0.0001   $ 0.0001
Purchase price, per unit | $ / shares $ 10.00    
MedTech Acquisition Corp | Raymond James Agreements      
COMMITMENTS AND CONTINGENCIES      
Deferred underwriting fees upon consummation of business combination $ 8,750,000    
MedTech Acquisition Corp | MTAC Class A Common Stock      
COMMITMENTS AND CONTINGENCIES      
Business combinations of warrant to purchase 0.33%    
Number of holdings | shares 1    
MedTech Acquisition Corp | Maximum | Raymond James Agreements      
COMMITMENTS AND CONTINGENCIES      
Aggregate fees received $ 4,500,000    
MedTech Acquisition Corp | Minimum | Raymond James Agreements      
COMMITMENTS AND CONTINGENCIES      
Aggregate fees received 3,000,000    
MedTech Acquisition Corp | TriSalus      
COMMITMENTS AND CONTINGENCIES      
Consideration payable $ 220,000,000    
Common stock, par value (in dollars per share) | $ / shares $ 0.0001    
Share price | $ / shares $ 10.00